Tepnel Life Sciences plc ("Tepnel" or the "Company")

Additional Listing and TVR

The New Ordinary Shares have been issued and allotted as fully paid up and rank pari passu in all respects with the existing issued ordinary share capital of the Company.

Application has been made by the Company for the admission of the 2,500,000 New Ordinary Shares to be admitted to the AIM market.  It is expected that Admission will become effective and that dealings in the New Ordinary Shares on AIM will commence on 10 September 2008.

Following Admission of the New Ordinary Shares, the total number of ordinary shares in issue and therefore the total number of voting rights will be 233,380,575.

For Further Information:

Tepnel Life Sciences plc

Ben Matzilevich, CEO

Michael Slater, Group Finance Director

Carol Smith, Group Marketing Communications Manager

0161 946 2200

Capital MS&L

Mary Clark or Joey Whineray

Tel: +44 20 7307 5330

Seymour Pierce Limited
Mark Percy
Tel: +44 20 7107 8000

Notes to Editors

About Tepnel Life Sciences plc

Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences products and services group with two main divisions, Molecular Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USA, UK and France over 200 employees.  Tepnel provides test kits, reagents and services to two highly synergistic markets, these being Molecular Diagnostics and Biomedical Research.  The Company's strategy has been to identify high growth niche opportunities within these multi-billion pound markets.  Tepnel focuses on these niche opportunities with internally developed products, patents, expertise and know-how as well as strategic acquisitions, to develop a leadership position within these defined market segments.

• News Channel